Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Octreotide - Novartis

Next Previous
Drug Profile

Octreotide - Novartis

Alternative Names: Octreotide acetate; Octreotide hydrochloride; Octreotide LAI; Octreotide Long Acting Injectable; Octreotide pamoate; Oncolar; Sandostatin LAR Depot; SMS 201995 ac; SMS 201995 pa; SMS 201995 pa LAR; SMS pa; SMS-201-995; SMS-995; SMS-995-AAA

Latest Information Update: 05 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis
  • Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
  • Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Intestinal obstruction; Malignant carcinoid syndrome; Neuroendocrine tumours
  • Discontinued Diabetic retinopathy; Diarrhoea; Malignant thymoma; Polycystic liver disease; Prostate cancer

Most Recent Events

  • 30 Mar 2023 Registered for Neuroendocrine tumours (Late stage disease) in European Union (IM) before March 2023
  • 10 Aug 2020 CASI Pharmaceuticals plans a registrational trial for Neuroendocrine tumours or Acromegaly in China in 2020
  • 16 Mar 2020 CASI Pharmaceuticals announces intention to obtain marketing approval for Acromegaly and Neuroendocrine tumours in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top